Galantamine / cognitive Cancer Research Results

Gala, Galantamine: Click to Expand ⟱
Features:
Galantamine
FDA approved drug for mild to moderate Alzheimer's Disease
- AChE inhibitor (reversible, competitive)
-May improve memory, cognition, and behavior
cognitive, cognitive: Click to Expand ⟱
Source:
Type:
Cognitive


Scientific Papers found: Click to Expand⟱
3748- CUR,  RES,  Hup,  Riv,  Gala  Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease
- Review, AD, NA
*AChE↓, *Inflam↓, *Aβ↓, *cognitive↑, *ROS↓,
3753- CUR,  Gala,    A Novel Galantamine–Curcumin Hybrid Inhibits Butyrylcholinesterase: A Molecular Dynamics Study
- Study, AD, NA
*BChE↓, *AChE↓, *Ach↑, *cognitive↑, *memory↑, *ROS↓, *Inflam↓, *NF-kB↓, *COX2?,
4248- Gala,    Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement
- Review, NA, NA
*BDNF↑, *cognitive↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 2,  

Transcription & Epigenetics ⓘ

Ach↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2?, 1,   Inflam↓, 2,   NF-kB↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   BChE↓, 1,   BDNF↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 3,   memory↑, 1,  
Total Targets: 11

Scientific Paper Hit Count for: cognitive, cognitive
3 Galantamine
2 Curcumin
1 Resveratrol
1 Huperzine A/Huperzia serrata
1 Rivastigmine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:344  Target#:557  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page